Why Is Twist Bioscience (TWST) Stock Down -13.30% Today?
Key Takeaways
- Shares plunged roughly 13.30% in Tuesday's session, sliding to about $177.74 from a prior close of $205.00.
- The decline reflects profit-taking after a parabolic run that had lifted the stock more than 500% year to date.
- A sector-wide risk-off move across high-growth healthcare and biotech names compounded the selling pressure.
- Elevated valuation and insider selling left little cushion when sentiment turned, amplifying the pullback.
- Traders are now watching for a stabilization of momentum, upcoming fiscal results, and any shift in broader biotech risk appetite.
Opening Summary
Twist Bioscience Corporation (TWST), a synthetic biology company that manufactures synthetic DNA on a silicon-based platform for drug discovery, diagnostics, and research applications, suffered a sharp reversal in Tuesday's session. After closing the prior session at $205.00 — a level that marked a fresh 52-week high — shares fell roughly 13.30% to around $177.74 intraday. The move lower followed weeks of extraordinary momentum, and markets attributed the decline primarily to profit-taking and a broader rotation out of high-multiple biotech names rather than any single company-specific development.
Profit-Taking After a Parabolic Run
The most immediate driver behind the pullback is the sheer scale of the stock's recent advance. TWST had climbed more than 500% year to date, surging from a 52-week low of $23.30 to a peak above $207.00, driven by enthusiasm around its synthetic-DNA platform and its agreement to support Eli Lilly's TuneLab AI drug-discovery initiative. When a stock appreciates that quickly, it becomes vulnerable to sharp givebacks on any shift in sentiment, and Tuesday's nearly $19 intraday swing underscored how crowded and momentum-driven the trade had become. With no new fundamental catalyst to sustain the rally, traders moved to lock in gains.
Sector-Wide Risk-Off in High-Growth Biotech
The decline in TWST did not occur in isolation. A broad retreat swept across higher-growth healthcare names, with peers such as NTRA, MRNA, and RVMD all falling sharply in tandem. This cluster of simultaneous declines points to sector-level selling concentrated in the more speculative corners of healthcare, rather than a company-specific event. Twist Bioscience, as one of the year's biggest biotech winners, was particularly exposed to this rotation, making it a natural target for de-risking when investors shifted away from high-valuation, loss-making growth stories.
Elevated Valuation and Insider Selling
Compounding the technical and sector pressures, TWST traded far above Wall Street's consensus value. The average analyst price target remained well below the stock's recent trading range near $200, leaving a wide gap between market pricing and Street expectations — and little margin for error when sentiment soured. Insiders have also been notable sellers during the advance, with the chief executive and president selling shares under pre-arranged plans, and prominent growth investors trimming positions. While such sales are not inherently bearish, they added to a perception that the stock had run ahead of its underlying fundamentals, which continue to include ongoing net losses despite solid revenue growth.
Market Context and Trading Activity
Trading volume was elevated relative to recent norms, consistent with heavy distribution as investors exited positions. The move reflected a divergence from broader, more defensive areas of the market, with the selling concentrated in high-beta, momentum-driven biotech names rather than across the entire healthcare complex. From a technical standpoint, the decline took TWST sharply off its recent highs and back below short-term breakout levels, though the stock remains well above its longer-term moving averages given the magnitude of its year-to-date rally.
What Comes Next for TWST
Investors will now watch whether the pullback stabilizes or signals a broader de-rating of the stock's momentum premium. Key considerations ahead include Twist Bioscience's upcoming quarterly results, management's progress toward profitability and adjusted EBITDA breakeven, and any further developments in its AI drug-discovery partnerships. The company continues to post strong revenue growth but has yet to translate that top-line momentum into consistent profitability — a balance that will remain central to how the market values the shares. Broader sector sentiment and the durability of investor appetite for high-growth biotech will also play a significant role in the near term.
Trending AI Robots
For traders seeking a more systematic approach to navigating volatile moves like this one, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing AI trading bots under current market conditions. Tickeron provides hundreds of AI-powered trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in the Trending AI Robots section, helping users quickly identify the strategies currently best aligned with the market environment. Explore the page to see which bots are leading today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for TWST turns positive, indicating new upward trend
TWST saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In 67 of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TWST just turned positive on September 17, 2026. Looking at past instances where TWST's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +9.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 233 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 182 of 226 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.738) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement